|
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole Clinical research trials and Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole clinical trial. Subjects frequently obtain the most expert healthcare possible for their Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole  Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
For Condition: Head and Neck Neoplasms,Squamous Cell Carcinoma,Metastases, Neoplasm
Status: Terminated
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The purpose of this clinical research study is to answer the following questions using 18F-fluoromisonidazole as an imaging agent: 1.) Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)? 2.) If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to control human tumors? And 3.) Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors? Hypoxic (low oxygen) cells have long been known to exist in animal tumors. It is also known that hypoxic cells are more difficult to eliminate with radiotherapy than tumor cells at normal levels of oxygen (normoxic cells). However, the extent to which hypoxic cells limit the curability of human tumors is uncertain. To determine if hypoxic cells exist in human tumors and how hypoxic cells might influence the efficacy of radiotherapy, this study involves direct measurements of oxygen levels in human tumors compared to the tumor uptake of the experimental drug, 18F-fluromisonidazole (18F-FMISO), visualized with PET scanning. 18F-fluoromisonidazole has been used with PET imaging to tell the difference between growing tumors which have high and low oxygen content. Before beginning radiotherapy, a PET scan (series of pictures, 20 min. scan) will be performed at 2 hours after an intravenous injection of a small amount of radioactive traces drug, 18F-fluoromisonidazole (18F-FMISO) to observe the active hypoxia tumors areas. Upon completion of the 18F-FMISO PET scan, direct oxygen measurements will be obtained by placing a small needle into the tumor under computer tomographic (CT) guidance. The PET scan and needle measurements will be repeated every 4 weeks into the course of radiotherapy and again after the completion of radiotherapy. The measurement obtained by 18F-FMISO PET scanning (non-invasive technique) and by direct needle measurements (invasive technique) will be correlated with the eventual treatment outcome for future use.
Details:
Eligibility:
Study Type: Interventional, Diagnostic, Non-Randomized, Open Label
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Histologically proven squamous cell carcinoma of head and neck wth metastatic neck nodes greater than or equal to 2cm - Karnofsky performance status greater or equal to 60% - No prior irradiation or surgery to head/neck area - No prior chemotherapy within 1 month of participation and have recovered from associated related effects - Not pregnant - Any intercurrent medical or physiologic disorder which would prevent informed consent - Underlying medical problems which would compromise technical ability to deliver a "standard course" of radiation therapy - Patients with PT or PTT over 1.5 times normal
Total Enrollment: 45
Location and Contact Information:
University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: ID93-028;
Study Start Date: January 1994
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038038
Other Head And Neck Neoplasms Studies:
1. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
2. Study Of Zd1839 (Iressaâ„¢) Versus Methotrexate For Previously Treated Patients With Squamous Cell Carcinoma Of The Head And Neck
3. Phase II Trial of Allovectin-7® for Head and Neck Cancer
4. Open-Label Phase 1 Dose Escalation Study of Intralesional Injection of M4N in Patients with Refractory Malignant Tumors of the Head and Neck
5. An Open-Label Phase 2 Study of Lonafarnib in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Related Studies:
Other Head and Neck Neoplasms Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
|
|
|
|
|
|
|
|
